Clinical trial · Observational
SUROVA - Surgery in Ovarian Cancer, Comparing Primary and Interval Cytoreductive Surgery
An International Retrospective Observational Study Comparing Primary Cytoreductive Surgery With Neoadjuvant Chemotherapy and Interval Cytoreductive Surgery in Patients With Carcinoma of the Ovary, Fallopian Tubes and Peritoneum
NCT06223763CI-TRIAL-00073316SUROVAunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Epithelial Ovarian Cancer | Ovarian Carcinoma | ALIAS | 0.90 |
| Fallopian Tube Neoplasms | Fallopian Tube Neoplasm | ONTOLOGY_EXACT | 0.98 |
| Peritoneal Neoplasms | Peritoneal Neoplasm | ONTOLOGY_EXACT | 0.98 |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Adjuvant chemotherapy | Drug | Adjuvant Chemotherapy | ALIAS |
| Cytoreductive surgery | Procedure | — | UNRESOLVED |
| Neoadjuvant chemotherapy | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- label
- Primary cytoreductive surgery
- description
- Patients underwent primary cytoreductive surgery between January 1, 2018, and December 31, 2019. After that, they underwent adjuvant therapy.
- interventionNames
- Procedure: Cytoreductive surgery
- Drug: Adjuvant chemotherapy
- label
- Interval cytoreductive surgery
- description
- Patients underwent primary first course of neoadjuvant chemotherapy between January 1, 2018, and December 31, 2019. After neoadjuvant chemotherapy, the patient underwent interval cytoreductive surgery and then, adjuvant chemotherapy.
- interventionNames
- Procedure: Cytoreductive surgery
- Drug: Neoadjuvant chemotherapy
- Drug: Adjuvant chemotherapy
Primary outcomes (1)
- measure
- Overall Survival at 5 years
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- Female
Show eligibility criteria text
Inclusion Criteria: * Patients \> 18 years old. * Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 at the time of the surgery. * Invasive high-grade epithelial ovarian cancer, fallopian tube carcinoma, or primary peritoneal carcinoma in stage International Federation of Gynecology and Obstetrics (FIGO) IIIB-IVB (IVB only if resectable metastases are present), suspected or histologically confirmed and newly diagnosed. * Patient underwent primary surgery or first course of neoadjuvant chemotherapy between January 1, 2018, and December 31, 2019. * American Society of Anesthesiologists Physical Status Classification System (ASA) score 1 or 2 at the time of the surgery. * Surgery performed by laparotomy with an attempt of maximal effort. * The surgeon must be a certified or non-certified gynecologic oncologist. * Based on all available information before the surgery (primary or interval), the patient was considered completely resectable. * Adequate bone marrow function: Absolute neutrophil count (ANC) ≥ 1.5 x 109/L. * Preoperative imaging (either CT, whole-body MRI, or positron emission tomography (PET)-CT) excluding unresectable disease as per European Society of Gynaecological Oncology (ESGO) criteria. * Surgical report on residual disease after surgery. Exclusion Criteria: * Non-epithelial malignant ovarian neoplasms and borderline tumors. * Secondary invasive neoplasms in the last 5 years (except synchronal endometrial carcinoma FIGO IA G1/2, non melanoma skin cancer, breast cancer T1 N0 M0 G1/2) or with any signs of relapse or activity. * Recurrent ovarian cancer. * Prior chemotherapy for ovarian cancer or abdominal/pelvic radiotherapy. * Unresectable parenchymal lung metastasis, liver metastasis or bulky lymph-nodes in the mediastinum in CT chest and abdomen/pelvis before surgery (primary or interval). * Pregnant women at the time of diagnosis.
References
Publications (2)
- DERIVEDChiva L, Ordas P, Mishra J, Ayhan A, Lee YY, Bogani G, Sp S, Lomnytska M, Stukan M, Fruscio R, Chura BF, Salcedo-Hernandez RA, De Iaco P, Haidopoulos D, Svintsitskiy V, Jain V, Stanciu P, Rawert FL, Akdemir C, Abdallah R, Chacon E, Minguez JA, Gil-Moreno A, Kharchenko K, Mofrad MH, Gebauer G, Diaz-Feijoo B, Scibilia G, Klaric M, Skof E, Saadeh FA, Mueller MD, Saarelainen S, Tejerizo Garcia A, Fotopoulou C, Coronado P, Dermikiran F, Goffin F, Tsolakidis D, Gonzalez-Martin A; SUROVA Study Group. SUROVA study: global real-world treatment strategies and mortality risk prediction in advanced ovarian cancer. Int J Gynecol Cancer. 2025 Dec;35(12):102688. doi: 10.1016/j.ijgc.2025.102688. PMID 41352872
- DERIVEDChiva L, Ordas P, Martin-Calvo N, Aramendia JM, Sanchez Lorenzo L, Gallego Martinez A, Vizcay A, Minguez JA, Manzour N, Vazquez-Vicente D, Chacon E, Castellanos T, Gonzalez Martin A. An international worldwide retrospective cohort observational study comparing primary cytoreductive surgery with neoadjuvant chemotherapy and interval cytoreductive surgery in patients with carcinoma of the ovary, fallopian tubes, and peritoneum (SUROVA trial). Int J Gynecol Cancer. 2024 Jun 3;34(6):942-945. doi: 10.1136/ijgc-2024-005354. PMID 38479803